|
CN111808192A
|
|
Antibodies that bind LAG3 and uses thereof
|
|
US10577424B1
|
|
Antibodies binding VISTA and uses thereof
|
|
US10570210B1
|
|
Antibodies binding CD40 and uses thereof
|
|
CN111454363A
|
|
Antibodies that bind CD40 and uses thereof
|
|
US10442866B1
|
|
Antibodies binding OX40 and uses thereof
|
|
CN109762067A
|
|
In conjunction with the antibody and application thereof of people Claudin 18.2
|
|
US2018022820A1
|
|
Bispecific anti-HER2 antibody
|
|
CN108570106A
|
|
Anti- Ebola virus monoclonal antibody, preparation method and the usage
|
|
CN106699891A
|
|
Anti-PD-L1 antibody as well as pharmaceutical composition and application of anti-PD-L1 antibody
|
|
CN107384932A
|
|
Anti-humen CD 20 Humanized monoclonal antibodies MIL62, preparation method and the usage
|
|
CN107446045A
|
|
A kind of anti-HER2 antibody, its pharmaceutical composition and purposes
|
|
CN106084058A
|
|
Anti-human PCSK9 monoclonal antibody
|
|
CN105399830A
|
|
Humanized anti-EGFR monoclonal antibody, preparation method and uses thereof
|
|
CN104208719A
|
|
ADC (antibody-drug conjugate) cation exchange chromatographic purification method
|
|
CN104726462A
|
|
Anti-HER2 humanized antibody MIL41, and preparation method and applications thereof
|
|
CN104278038A
|
|
Variable region coding gene of human vascular endothelial growth factor (VEGF)-resistant humanized antibody and use thereof
|
|
CN101974535A
|
|
Preparation and application of novel anti-ErbB2 humanized antibody MIL12
|
|
CN101948540A
|
|
Preparation of novel anti-EGFR human source antibody MIL27 and application thereof
|
|
CN101875697A
|
|
Design of novel anti-EGFR humanized antibody TGM10 and application thereof
|
|
CN101633695A
|
|
Preparation method of anti-erbB2 functional antibody based on erbB2 protein extracellular C-terminal functional epitope characteristics
|
